KR20040080641A - Composition comprising an extract of Euonymus alatus for prevention and treatment of diabetes - Google Patents

Abstract

PURPOSE: A composition containing the extract of Euonymus alatus (Thunb.) Sieb. as a main component is provided. The Euonymus alatus extract exhibits antidiabetic activity in OGTT(Oral Glucose Tolerance Tests) and streptozotocin-induced diabetic rats and significantly reduces the glucose level in blood and urine and can be used in prevention and treatment of diabetes. CONSTITUTION: The pharmaceutical composition for the prevention and treatment of diabetes contains 0.1 to 50% by weight of a Euonymus alatus extract, pharmaceutically acceptable carriers or excipients. The Euonymus alatus extract is a crude extract or an extract soluble in a polar solvent such as water, lower alcohol or a mixed solvent thereof. The dosage of the pharmaceutical composition is administered in an amount of 0.1 to 100mg/kg per day. The health food for reducing blood glucose level and preventing diabetes contains a Euonymus alatus extract which is soluble in a polar solvent and a food acceptable additive. The Euonymus is Euonymus alatus (Thunb.) Sieb., Euonymus bungeanus MAXIM. or Euonymus sieboldianus BLUME.

Description

Composition comprising an extract of Euonymus alatus for prevention and treatment of diabetes}

The present invention relates to a composition for preventing and treating diabetes containing crude extract of Euonymus alatus (THUNB.) SIEB. Or a polar solvent soluble extract having hypoglycemic activity.

Diabetes is a disease caused by abnormally high levels of glucose in humans and mammals, which increases the level of hemoglobiin in plasma and chronic hyperglycemia (hyperglycemia). ), A series of complications such as atherosclerosis, microang iopathy, kidney disease, heart disease, diabetic retinopathy and other eye diseases.

Diabetes mellitus is characterized by two types: insulin dependent diabetes (IDDM) is caused by a deficiency of insulin, a glucose-regulating hormone in the blood, mainly in the 10s to 20s. It is called juvenile diabetes because it occurs in younger ages. Type 2 diabetes (non-insulin dependent diabetes, NIDDM) usually occurs after the age of 40, and occupies most of the diabetic patients in Korea. Unlike type 1, it is called adult-type diabetes and the cause of the disease is not clear yet, but it is known that it is caused by genetic factors and environmental factors. The etiology of type 2 diabetes has been observed in both pancreatic beta cells with impaired insulin secretion and defective insulin action (insulin resistance) in target cells, but it is not yet clear which changes are of primary importance.

Agents currently used for complications such as type 2 diabetes and insulin resistance include five groups of compounds: biguanides, thiazolidined iones, sulfonylureas, and benzoic acid. Derivative compounds and α-glucosidase inhibitors are used. Among these, biguanide compounds, such as metformin, act on the gluconeogene sis in the liver to regulate blood glucose. It is a known drug. Thiazolidinedione compounds are thought to act to increase glucose utilization in peripheral nerves, benzoic acids such as sulfonylureas, repaglinide compounds such as tolbutamide and glyburide Derivatives stimulate insulin secretion to lower blood glucose, whereas α-glucosidase inhibitors such as acarbose are drugs that control post-prandial blood sugar by blocking the breakdown of carbohydrates in the small intestine.

The sulfonylurea compound may not be administered to insulin-dependent type 1 diabetic patients, and non-insulin-dependent type 2 diabetic patients may decrease insulin secretion and abnormal fetal birth, abortion, and May cause side effects such as stillbirth. In addition, most sulfonylurea compounds should be administered carefully to patients with impaired liver and kidney function due to the metabolism of sulfonylurea.

Although the mechanism of biguanide-containing preparations such as metformin has not been elucidated, although biguanide compounds are unable to increase pancreatic insulin secretion, they lower blood sugar levels more effectively than sulfonylurea and also induce hypoglycemia. low. However, it can cause nausea, vomiting, diarrhea and rash at the beginning of administration, and can cause side effects such as fatal lactic acidosis, so it can only be used as a clinical reagent in the United States.

Since sulfonylurea and biguanide-containing preparations have the above disadvantages and side effects, there is a need for an excellent hypoglycemic agent having low side effects and high safety.

Arrowwood used in the present invention (Truewood, Euonymus alatus (THUNB.) SIEB.) Is a deciduous shrub with a lone tree, Novak, and is distributed in Korea, Japan, Sakhalin and China. Young leaves are herbs and the wings of branches are called earheads. The leaves contain epipriedelanol, priedelin, quercetin and dulcitol. Seed oil contains saturated fatty acids (20%), oleic acid, linoleic acid, linolenic acid, capric acid and benzoic acid. Oriental medicine is used for hemostasis, gore blood, pain.

In this regard, the present inventors have no side effects and anti-diabetic activity in oral glucose tolerance test (OGTT) and streptozotocin-induced diabetic rats was isolated by extracting the polar solvent-soluble extracts from arrowwood to develop a safe natural drug for diabetic disease It was confirmed that the reduction in blood sugar and urine glucose, and confirmed that the excellent therapeutic and prophylactic efficacy for diabetes diseases to complete the present invention.

It is an object of the present invention to provide a pharmaceutical composition and a dietary supplement that is effective for the prevention and treatment of diabetes diseases containing the extract of arrowwood.

1 is a diagram showing the effect on blood glucose when oral administration of the ethanol extract of arrowwood to ICR mice by dose,

Figure 2 is a diagram showing the area under each glucose response curve for each dose from 0 minutes to 90 minutes in Figure 1,

3 is a diagram showing the effect on blood glucose when oral administration of ethanol extract, water fraction and ether fraction of arrowwood extract,

Figure 4 is a diagram showing the area under the glucose response curve per sample from 0 to 90 minutes in Figure 3,

5 is a diagram showing the effect on blood glucose when orally administered water fractions of the arrowwood extract,

Figure 6 is a diagram showing the area under each glucose response curve for each dose from 0 minutes to 90 minutes in Figure 5,

7 is a diagram showing the effect of arrowwood extract on body weight in streptozotocin-induced diabetic rats,

8 is a diagram showing the effect of arrowwood extract on blood glucose in streptozotocin-induced diabetic rats.

In order to achieve the above object, the present invention provides a composition for preventing and treating diabetes mellitus and diabetic disease containing crude extract or polar solvent soluble extract of arrowwood with hypoglycemic activity.

The crude extract of arrowwood is preferably an extract available in a polar solvent such as water, methanol, ethanol and the like, and a mixed solvent thereof, preferably a 70% ethanol mixed solvent.

In addition, the polar solvent soluble extract of the arrowwood includes a polar solvent such as water, methanol, ethanol and the like remaining after removing the non-polar solvent soluble portion from the crude extract and a mixture thereof, preferably an extract available in water.

The nonpolar solvent soluble part includes an extract which is soluble in a nonpolar solvent such as ethyl acetate, chloroform, hexane, ether, or a mixed solvent thereof, preferably an ether solvent.

The sapling tree includes plants such as Euonymus alatus (THUNB.) SIEB., Euonymus bungeanus MAXIM., And E. sieboldianus BLUME.

The method of separating the crude extract and the polar solvent soluble extract of the arrowwood is as follows.

Hereinafter, the present invention will be described in more detail.

The crude extract of the arrow tree of the present invention,

About 1 to 20 times the volume of the dried and crushed arrowwood (kg), preferably 5 to 10 times water, a polar solvent such as methanol or ethanol or a mixed solvent thereof, and then 20 to 100 ° C., Preferably 40 to 60 ℃, about 1 hour to 3 days, preferably for 1 hour to 1 day, filtered by extraction method such as hot water extraction, ultrasonic extraction, reflux cooling extraction once or five times and reduced pressure By drying or lyophilization, the arrowwood crude extract of the present invention can be obtained.

In addition, the arrowwood polar solvent soluble extract of the present invention, the crude extract is dissolved in a polar solvent such as water, methanol, ethanol or a mixed solvent thereof, the same amount of non-polar solvent such as ether, ethyl acetate, chloroform, hexane After the addition, the mixture was fractionated for 1 hour to 48 hours to obtain a polar solvent soluble layer and a non-polar solvent soluble layer, respectively.

It was confirmed that the anti-diabetic activity was tested in the glucose tolerance test (OGTT) and streptozotocin-induced diabetic rats with the isolated polar solvent-soluble extract of arrowwood, and reduced the blood sugar and urine glucose to diabetic disease It was found to have excellent therapeutic and prophylactic effects.

The present invention provides a blood glucose lowering composition containing the polar solvent soluble extract of arrowwood prepared by the above method as an active ingredient.

The present invention provides a pharmaceutical composition for the prevention and treatment of diabetes mellitus and diabetic disease containing the arrowwood polar solvent soluble extract prepared by the above method as an active ingredient.

In addition, the composition for lowering blood glucose, the pharmaceutical composition for preventing and treating diabetes mellitus and diabetic diseases, containing the arrow-tree polar solvent soluble extract of the present invention comprises 0.1 to 50% by weight of the extract based on the total weight of the composition.

In particular, the diabetic diseases are complications such as diabetic retinopathy, diabetic neuropathy, nephropathy, atherosclerosis, myocardial disorders, skin disorders, diabetic foot syndrome, and peripheral vascular diseases as diabetes progresses chronically. Also included.

The composition comprising the arrowwood polar solvent soluble extract of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.

Carriers, excipients and diluents that may be included in the composition comprising the polar solvent soluble extract of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, Gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

Compositions comprising extracts according to the invention are formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterile injectable solutions, respectively, according to conventional methods. Can be used.

The amount of the extract of the present invention may vary depending on the age, sex, and weight of the patient, but in general, an amount of 0.01 to 500 mg / kg, preferably 0.1 to 100 mg / kg, may be administered once or several times a day. Can be. In addition, the dosage of the extract can be increased or decreased depending on the route of administration, the degree of disease, sex, weight, age and the like. Therefore, the above dosage does not limit the scope of the present invention in any aspect.

The pharmaceutical composition of the present invention can be administered to mammals such as rats, mice, livestock, humans by various routes. All modes of administration can be expected, for example by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.

In addition, the arrowwood polar solvent soluble extract of the present invention can be used as a main, secondary raw material and food additive of other foods.

In another aspect, the present invention provides a health functional food for the prevention of blood sugar lowering and diabetes, including the arrow-tree polar solvent soluble extract and a food supplement acceptable food supplement.

The composition comprising the extract of the present invention may be used in various ways, such as drugs, food and beverages for the prevention and treatment of diabetes. Examples of the food to which the present extract can be added include various foods, beverages, gums, teas, vitamin complexes, and health functional foods.

Extract itself of the present invention is a drug that can be used with confidence even for long-term administration for the purpose of prevention because there is little toxicity and side effects.

The extract of the present invention may be added to food or beverage for the purpose of preventing diabetes.

The health beverage composition of the present invention is not particularly limited in the liquid component except for containing the extract as an essential ingredient, and may contain various flavors or natural carbohydrates, etc., as additional ingredients, as in ordinary beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of said natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and salts thereof. , Organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. The compositions of the present invention may also contain pulp for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected from the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.

The present invention is described in more detail based on the following examples, although the present invention is not limited thereto.

Reference example. Statistical processing

The results of all experiments were expressed as mean ± standard deviation and statistical processing was performed by Student's t-test to determine the significance based on p <0.05 (* is P <0.05, ** is P <0.01, *** means P <0.001, which is significantly different from the control).

Example 1 Preparation of Arrowwood Crude Extract

Arrowwood samples were supplied from the Korean Institute of Herbal Medicine. After extracting 400 g of dried and dried arrowwood powder with 3L of 70% ethanol twice over 4 hours in a water bath with a cooler, the extract was filtered through a filter paper (Whatman type 2), dried under reduced pressure, and lyophilized to dryness. A powder was obtained, which was used for the following experiment.

Example 2. Preparation of arrowwood polar solvent soluble extract (2-1)

After dissolving 18 g of the ethanol extract in the same amount of water and ether, the mixture was freeze-dried from the water fraction and the ether fraction obtained by standing in a fractional filter for 12 hours, respectively, 12.8 g of the water fraction (2-1) (400 g of the first arrow tree). 6.4%), ether fraction (2-2) was obtained 4g (2% of the 400 g of the first arrow). All samples were stored at 4 ℃ and dissolved in distilled water at the time of experiment immediately used in the experiment.

Experimental Example 1. Oral Glucose Tolerance Test (OGTT) of Arrow Extract

1-1. Laboratory animals

Five-week-old ICR mice were purchased (Dae Biolink, Chungbuk Negative), and were acclimated for one week in the laboratory, and then orally administered samples dissolved in primary distilled water. The experimental animals were bred in animal kennels maintained at a humidity of 50% and a temperature of 24 ~ 26 ℃, and water was supplied for free intake.

Before the experiment, the animals were fasted for 12 to 13 hours, the blood glucose levels were measured from the blood obtained by orbital blood collection, and each animal group was divided into a control group, a positive control drug group, and a sample administration group.

1-2. Oral glucose tolerance test

Samples of arrowwood samples of Examples 1 and 2 prepared 30 minutes before the start of the experiment were orally administered at concentrations of 500 mg / kg, 1000 mg / kg, and 2000 mg / kg, followed by glucose (1.5 g) in each group at the time point of 0 minutes. / kg, Sigma) and the orbital blood collection at 0 minutes concurrent with the administration and the orbital blood collection at 30 minutes, 60 minutes, and 90 minutes to measure the blood glucose changes were observed. Blood was collected from heparin-treated capillaries from orbital veins of experimental animals. The collected blood was centrifuged at 5000 rpm and 4 ° C. for 5 minutes (Microcentrifuge 5417R, Eppendorf, Germany) and used for the experiment. Blood glucose was measured by the glucose oxidase method (Trinder, Sigma Diagnostic, St. Louis, MO) (Kakkar R. et al . ; Life Sci. , 60 (9) , pp667-679, 1997). .

1 and 2 are experimental results conducted to determine whether the 70% ethanol extract of arrowwood shows a dose-dependent tendency with the concentration of 500 mg / kg, 1000 mg / kg, 2000 mg / kg, OGTT test results Shows the change in blood sugar and the area under the curve. It can be seen that the significance is shown at the concentration of 1000 mg / kg and 2000 mg / kg. The decrease in the area under the curve was 6.5%, 19.8%, and 19.3% after the administration of the sample at each concentration, and dose-dependent hypoglycemic activity was shown, but there was a big difference between 1000 mg / kg and 2000 mg / kg concentrations. Did not appear.

3 and 4 are the results of the OGTT according to the concentration in consideration of the fraction (700 mg / kg water, 300 mg / kg ether) fraction with the arrowwood fraction obtained by dividing the arrowwood into ether and water layer. The change in blood glucose and the area under the curve are shown. As shown in the figure, the 700 mg / kg water layer showed almost the same hypoglycemic activity as compared to the group administered 1 g / kg of 70% ethanol, indicating that most of the hypoglycemic active ingredients were transferred to the water layer. Therefore, in subsequent experiments, a dose-dependent experiment was conducted using the water layer.

5 and 6 show the blood glucose change and the area under the curve obtained by OGTT by dividing the water layer of the arrowwood containing the active fraction into concentrations of 250 mg / kg, 500 mg / kg and 700 mg / kg. will be. Glimepiride was used as a positive control drug. As shown in Figure 6, the dose-dependent polar solvent soluble extract suppressed the blood glucose increase.

Table 1 below shows the plasma insulin concentration at 0 and 30 minutes in the OGTT experiment. In the group administered 500 mg / kg and 700 mg / kg arrowwood, insulin levels were increased 1.2 times and 1.6 times at 0 minutes and 1.2 times and 1.3 times at 30 minutes, respectively, compared to the control group. Insulin levels were significantly increased in the group administered with the arrow tree and the group administered the glimepiride, a positive control drug.

group Insulin (μ IU / ml) 0 min 30 minutes Control 8.4 ± 0.5 13.2 ± 1.6 Arrowwood extract 250 mg / kg 8.9 ± 0.7 13.9 ± 0.5 Arrowwood extract 500 mg / kg 9.7 ± 0.4 16.1 ± 0.4 Arrowwood extract 700 mg / kg 13.4 ± 0.2 ** 17.4 ± 0.7 * Glimepiride 22.0 ± 1.1 * 21.1 ± 0.5 **

Experimental Example 2. Screening of antidiabetic activity of arrowwood active fractions in Multiple Low Dose Streptozotocin-induced Diabetic Rats

2-1. Laboratory animals

Male Spraque-Dawley rats weighing 150-160 g were purchased from Daehan Biolink and adapted for 1 week in the laboratory, followed by oral administration of sample samples dissolved in primary distilled water. Experimental animals were bred in animal kennels maintained at a humidity of 50% and a temperature of 24 ~ 26 ℃, and water was supplied for free intake. Randomly divided SD rats were divided into normal control (NC), diabetic control (DC), co-treatment group (CO) and post-treatment group (POST). Separated.

2-2. Measure changes in dietary and negative intake

Each experimental group was intraperitoneally administered with streptozotocin (streptozotocin) at a concentration of 25 mg / kg in 100 mM citric acid buffer (citrate buffer) for 5 days. Rats receiving citric acid buffer were used as a control group, and the post-treatment group started administration from the time when diabetes was induced (blood glucose level of 240 mg / dL or more). In this experiment, 300 mg / kg arrowhead was intraperitoneally administered. Blood glucose and body weight were measured after 6 hours of fasting every 5 days, and diet and drinking volume were measured at the end of the administration of the sample.

Table 2 below shows the changes in dietary and negative amounts obtained after 3 weeks of the experiment. The normal control group did not show significant changes during the experiment, whereas the diabetic control group showed a significant increase in dietary and negative intake. In the simultaneous treatment group and the post-treatment group, the intake of dietary and drinking water was reduced compared to the diabetic control group.

Dietary Intake (g / rat / day) Drinking water intake (ml / rat / day) NC 22.0 ± 0.6 34.7 ± 1.5 DC 30.3 ± 0.3 185.0 ± 6.7 CO 23.3 ± 1.5 117.0 ± 1.5 NC 21.3 ± 1.2 30.0 ± 2.3 DC 30.3 ± 0.9 178.0 ± 1.2 POST 26.0 ± 0.6 121.7 ± 2.0

2-3. Body weight and blood sugar change measurement

7 shows the weight change. The experimental animal group treated with streptozotocin (25 mg / kg) showed no tendency to gain weight but rather decreased slightly compared to the untreated animal group. At 15 days after the experiment, there was no significant difference between the diabetic control group and the treatment group, but the weight gain was slightly increased in the simultaneous treatment group and the post-treatment group. 8 shows the change in blood glucose. During the experiment, the blood glucose level of the diabetic control group was higher than that of the other groups, and the blood glucose level of the diabetic control group was suppressed from 3 weeks after the administration of the sample. On the 20th day, the co-treated group (258.0 ± 80.0, P <0.05) showed significantly lower values than the diabetic control group (402.3 ± 42.6). Yes (288.3 ± 56.8, P = 0.0532).

Table 3 shows fasting blood glucose and body weight at the end of the experiment. Fasting blood glucose of the diabetic control group was significantly higher than that of the normal control group. On the other hand, fasting blood glucose was significantly decreased in the simultaneous and post-treatment groups compared to the diabetic control group. In the change of body weight, the body weight of the simultaneous treatment group and the post-treatment group was significantly increased compared to the diabetic control group.

Blood sugar (mg / ㎗) Body weight (g) NC 105.3 ± 3.4 274.8 ± 4.8 DC 402.3 ± 42.6 170.8 ± 4.9 CO 258.0 ± 80.0 185.0 ± 1.0 NC 107.3 ± 3.8 295.3 ± 2.9 DC 412.3 ± 30.6 164.0 ± 4.7 POST 288.3 ± 56.8 191.3 ± 2.7

Experimental Example 3. Urine sampling

At the end of the experiment, rats were placed in a metabolic cage for 24 hours to receive urine to measure glucose in the urine, and diabetes was measured using a glucose measurement kit (Trinder, Sigma).

Table 4 shows the urine glucose concentration after the end of the administration. Compared with the normal control group, the urine glucose level in the diabetic control group was significantly increased. Compared to the diabetic control group, the simultaneous treatment group (5.8 ± 0.5) showed lower values and the post-treatment group (10.6 ± 1.4) did not show any significant change.

group Diabetes (g / day) NC 0.0 ± 0.0 DC 13.5 ± 1.9 CO 5.8 ± 0.5 ** POST 10.6 ± 1.4

Experimental Example 4. Measurement of Kidney Hypertrophy Index

In order to measure kidney hypertrophy at the end of dosing, rats were sacrificed to measure kidney hypertrophy, and the kidneys were removed to measure their weight and weight, and then the percent kidney ratio (%, weight percentage of total weight to total weight) was calculated.

Table 5 compares the results of renal hypertrophy between groups after the end of the administration. The renal hypertrophy of the diabetic control group was higher than that of the normal control group and the renal hypertrophy of the diabetic control group was 11.6% and 10.2%, respectively.

Body weight (g) Kidney Weight (g) Renal hypertrophy (%) NC 295.3 ± 2.9 1.27 ± 0.04 0.43 ± 0.01 DC 164.0 ± 4.7 1.13 ± 0.01 0.69 ± 0.02 CO 185.0 ± 1.0 1.13 ± 0.01 0.61 ± 0.01 * PO 191.3 ± 2.7 1.18 ± 0.01 0.62 ± 0.01 *

Experimental Example 5. Acute Toxicity Test

1. Oral administration

ICR-based mice and Sprague-Dawley rats were divided into four groups of 10 rats each, followed by oral administration of arrowwood water extracts of the present invention at doses of 500, 725, 1000 and 5000 mg / kg, respectively. As a result, none of the four groups died, and no symptoms were apparent from the control group.

2. Intraperitoneal administration

ICR mice (weight 25 ± 5 g) and Sprague dooli rats were divided into four groups of 10 rats each, followed by intraperitoneal administration of the arrowwood extract of the present invention at doses of 25, 250, 500 and 725 mg / kg, respectively. For 24 hours, no toxicities were observed in all four groups and no symptoms were apparent from the control group. As a result, it was confirmed that the extract of the present invention of the present invention has little acute toxicity.

Examples of the formulations of the above pharmaceutical formulations are described below, but are not intended to limit the present invention but to explain in detail only.

Formulation Example 1 Preparation of Injection

Example 2 Arrowwood extract ..... 100 mg

Sodium metabisulfite ........ 3.0mg

Methylparaben ............... 0.8 mg

Propylparaben ...................... 0.1 mg

Sterile distilled water for injection ..............

The above ingredients are mixed and made into 2 ml by a conventional method, and then filled into 2 ml ampoules and sterilized to prepare an injection.

Formulation Example 2 Preparation of Tablet

Example 2 Arrowwood Water Extract ... 200 mg

Lactose 100 mg

Starch .............................. 100 mg

Magnesium Stearate ...............

The above components are mixed and tableted according to a conventional method for producing tablets to produce tablets.

Formulation Example 3 Preparation of Capsule

Example 2 Arrowwood Water Extract ... 100 mg

Lactose 50 mg

Starch ........................................ 50 mg

Talc ........................................ 2mg

Magnesium Stearate ...............

Capsules are prepared by mixing the above ingredients and filling into gelatin capsules according to a conventional method for preparing capsules.

Formulation Example 4 Preparation of Liquid

Example 2 Arrowwood Water Extract...

Sugar .................................. 20g

Isomerized sugar ......................................... 20 g

Lemon Flavor ......................

Purified water is added to the whole ........... 100ml

The above components are mixed according to a conventional method for preparing a liquid, filled into a 100 ml brown bottle, and sterilized to prepare a liquid.

The polar solvent soluble extract of the arrowwood according to the present invention shows antidiabetic activity in the OGTT test, streptozotocin-induced diabetic rats, and can be effectively used for the prevention and treatment of diabetes diseases by significantly reducing blood glucose and urine glucose.

Claims (7)

A pharmaceutical composition for the prevention and treatment of diabetes mellitus and diabetic diseases containing crude extract of arrowwood or polar solvent soluble extract as an active ingredient, and containing a pharmaceutically acceptable carrier or excipient. The composition of claim 1, wherein the polar solvent is water, methanol, ethanol or a mixed solvent thereof. The composition of claim 2, wherein the polar solvent is water. The composition of claim 1, wherein the arrowwood is Euonymus alatus (THUNB.) SIEB., Euonymus bungeanus MAXIM. Or E. sieboldianus BLUME. 5. The composition of claim 4, wherein the arrowwood is a red oak tree. A dietary supplement comprising crude extracts or polar solvent soluble extracts of arrowwood for the prevention of hypoglycemia, diabetes and diabetic diseases and food supplements. The health functional food of Claim 6 which is a health drink.